Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Research Disclaimer This compound is provided as a chemical reagent for in vitro laboratory research only
8.61 ~ 10 min, 30%B
these effects are dose-dependent and resolve with dose reduction
Joint and Soft Tissue Support
After FDA approval of enasidenib, a first-in-class drug targeting cancer metabolism via inhibition of IDH2 activity, more studies were conducted with R-2-HG positioned as an oncometabolite
US$ 23.35
US$ 20.89
US$ 29.92
US$ 24.18
US$ 21.77
US$ 28.12
US$ 20.95
